| Description | Sevoflurane is a rapidly acting, potent inhalation anesthetic with rapid uptake and and elimination. While somewhat less potent than halothane, sevoflurane does not induce arrhythmias and reportedly has no effect on renal function. |
| Description | Sevoflurane is a halogenated ether with anesthetic properties. It enhances the activity of GABAA and glycine receptors and inhibits the activity of nicotinic acetylcholine receptors (nAChRs) and glutamate receptors. Sevoflurane enhances the responses of α2β1 subunit-containing GABAA and α1 subunit-containing glycine receptors at submaximal agonist concentrations in HEK293 cells (EC50s = 0.45 and 0.36 mM, respectively). Sevoflurane (360 μM) also increases the amplitude of GABAA receptor responses to GABA stimulation for receptors with an α1β2γ2 subunit composition. It inhibits binding of the high affinity nicotinic agonist epibatidine to nAChRs in mouse brain membranes (IC50 = 0.77 mM). Formulations containing sevoflurane have been used in the induction and maintenance of general anesthesia. |
| Chemical Properties | Clear, colourless, volatile liquid. |
| Originator | Baxter (USA) |
| Uses | 1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane is an volatile anesthetic which inhibited activation of inflammatory neutrophil and granulocyte in human blood during simulated extracorporeal circulati on. |
| Uses | Fluoromethyl 1,1,1,3,3,3-hexafluoroisopropyl ether is a volatile anesthetic, which inhibits the activation of inflammatory neutrophil and granulocyte in human blood during simulated extracorporeal circulation. It also serves as an antibacterial and used as an inhalational anaesthetic for induction and maintenance of general anesthesia. Further, it finds application in anesthesia of children and infants to make them asleep for surgery. In addition to this, it is used in veterinary medicine. |
| Definition | ChEBI: An ether compound having fluoromethyl and 1,1,1,3,3,3-hexafluoroisopropyl as the two alkyl groups. |
| Manufacturing Process | 164 g (2.31 mole) of chlorine is slowly bubbled into a flask containing 370 g (2.03 mole) of methyl 1,1,1,3,3,3-hexafluoroisopropyl ether illuminated with a 250 watt incandescent lamp, starting at room temperature. The product is washed with a potassium carbonate solution until neutral, dried over MgSO4 and vacuum distilled to yield 304 g (1.5 mole) of chloromethyl 1,1,1,3,3,3- hexafluoroisopropyl ether (chloromethyl 1,1,1,3,3,3-hexafluoro-2-propyl ether), boiling point 78°C.
A solution of chloromethyl 1,1,1,3,3,3-hexafluoro-2-propyl ether (754 g, 3.49 moles) in dry tetrahydrothiophene 1,1-dioxide (203 g, 3,49 moles) were stirred and heated to 130°C in a creased flask fitted with a fractional distillation assembly. A distillate (200 ml), b748 56.0° to 62°C, was collected during 5 h. Then the reaction mixture was cooled to room temperature, dry potassium fluoride (100 g, 1.74 moles) was added, and the cycle of operations was repeated 3 times at temperatures between 138° to 185°C to give distillates (100 ml, 100 ml and 50 ml), b746 58° to 61°C, 55.5° to 57°C, and 54.2° to 55.9°C, respectively. From this portionwise addition of potassium fluoride (503 g, 8.7 moles) there was obtained distillates totalling 672 g, b746 54.2° to 62.0°C, which by GLC analysis was about 92% fluoromethyl and 6.8% chloromethyl 1,1,1,3,3,3-hexafluoro-2-propyl ether.
Fractional distillation of 659 g gave a forerun (46 g), b745 53.5° to 57.0°C, and then 99.6% pure fluoromethyl 1,1,1,3,3,3-hexafluoro-2-propyl ether (505 g), b745 57.0° to 57.7°C. |
| Brand name | Ultane (Abbott);Sevofrane. |
| Therapeutic Function | Anesthetic |
| Biological Functions | Sevoflurane (Ultane) is the most recently introduced inhalation anesthetic. It has low tissue and blood solubility, which allows for rapid induction and emergence and makes it useful for outpatient and ambulatory procedures. It has the advantage of not being pungent, a characteristic that permits a smooth inhalation induction, and is particularly useful in pediatric anesthesia.
Hypotension is produced by sevoflurane as systemic vasodilation occurs and cardiac output decreases. Since it does not directly produce tachycardia, it is a useful alternative to consider in patients with myocardial ischemia. However, a concern for reflex-induced tachycardia remains.
Sevoflurane undergoes hepatic biotransformation (about 3% of the inhaled dose), and it is somewhat degraded by conventional CO2 absorbents. The degradation product from the absorbent has been reported to be nephrotoxic, although the report is controversial and not substantiated by more recent studies. Sevoflurane’s actions on skeletal muscle and on vascular regulation within the CNS are similar to those described for the other halogenated hydrocarbon anesthetics. |
| General Description | Sevoflurane is a volatile, nonpungent, nonflammable, andnonexplosive liquid with a boiling point of 58.6°C. Theblood:gas partition coefficient is 0.65, the oil:gas partitioncoefficient is 50, and the MAC is 2.1%. Sevoflurane reactswith desiccated carbon dioxide adsorbents, to produce compounds(A and B) with known toxicity . The typeof CO2 absorbent used, the temperature of the absorbent,and the duration of exposure can influence the degree towhich sevoflurane breaks down. The major breakdownproduct, compound A, pentafluoroisopropenyl fluoromethylether, (PIFE, C4H2F6O) has been studied extensively.Compound A is nephrotoxic in rats and nonhuman primatesand remains a theoretical risk to humans. As discussedpreviously under the stability of inhaled anesthetics,sevoflurane breakdown by CO2 absorbents generates heatand has resulted in sporadic operating room fires. |
| Clinical Use | Sevoflurane has been shown to cause epileptic changeson EEGs and case reports of seizures during surgery, especiallyin children, have been reported. |
| Veterinary Drugs and Treatments | Sevoflurane may be useful in a variety of species when rapid induction and/or rapid recoveries are desired with an inhalational anesthetic. |
China
